Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26781561 | 0.83 | TGFBR1 (0.39) | GRIA1CNR2NPSR1L3MBTL1POLB | |
| SCHEMBL7353645 | 0.82 | ECE1 (0.46) | GRIA1CNR2NPSR1ECE1 | |
| SCHEMBL7349775 | 0.82 | ECE1 (0.46) | GRIA1CNR2NPSR1ECE1 | |
| SCHEMBL10223263 | 0.80 | ALDH1A1 (0.41) | CNR2 | |
| SCHEMBL24824249 | 0.80 | HPGDS (0.42) | GRIA1 | |
| SCHEMBL8023218 | 0.77 | NPSR1 (0.33) | CNR2NPSR1 | |
| SCHEMBL13990408 | 0.76 | GRIA1 (0.39) | GRIA1 | |
| SCHEMBL16237277 | 0.76 | ALOX15 (0.45) | ECE1 | |
| SCHEMBL26206773 | 0.75 | CTSK (0.46) | — | |
| SCHEMBL25590141 | 0.74 | CNR2 (0.35) | GRIA1CNR2NPSR1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | UNIV CALIFORNIA (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | SNCA, PARK7, SYNCRIP | GRIA1 2061/4885CNR2 4040/4885NPSR1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.